Drug Trial Radar · NCT01272219
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Last checked: Nov 19, 2026Latest source record: Jan 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,731
Actual
Start
Jun 1, 2011
Primary completion
Mar 18, 2013
Study completion Mar 2, 2015
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jan 7, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America. The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese subjects or overweight subjects with co-morbidities. Furthermore, the aim is to investigate the long term potential of liraglutide to delay the onset of type 2 diabetes in subjects diagnosed with pre-diabetes at baseline. Based on body mass index (BMI) and pre-diabetes status, subjects will be randomised to either 68 weeks (56 weeks of randomised treatment followed by a 12 week re-randomised treatment period) or 160 weeks of treatment (160 week treatment will only be applicable to subjects with pre-diabetes status at baseline).
Conditions
- Metabolism and Nutrition Disorder
- Obesity
Interventions
liraglutideDrug
Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide 3.0 mg for 12 weeks (until week 68).
placeboDrug
Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide placebo for 12 weeks (until week 68).
liraglutideDrug
Liraglutide 3.0 mg, subcutaneous (under the skin) injection once daily for 160 weeks.
placeboDrug
Liraglutide placebo, subcutaneous (under the skin) injection once daily for 160 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Fasting Body WeightTime frame: Week 0, Week 56
- Proportion of Subjects Losing at Least 5% of Baseline Fasting Body Weight.Time frame: At Week 56
- Proportion of Subjects Losing More Than 10% of Baseline Fasting Body WeightTime frame: At 56 weeks
- Proportion of Subjects With Onset of Type 2 DiabetesTime frame: At 160 weeks
Locations
226 sites in 29 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Birmingham, Alabama
Novo Nordisk Investigational Site
Phoenix, Arizona
Novo Nordisk Investigational Site
Anaheim, California
Novo Nordisk Investigational Site
Concord, California
Novo Nordisk Investigational Site
Huntington Beach, California
Novo Nordisk Investigational Site
La Jolla, California
Novo Nordisk Investigational Site
San Diego, California
Novo Nordisk Investigational Site
San Diego, California
Novo Nordisk Investigational Site
Santa Monica, California
Novo Nordisk Investigational Site
Aurora, Colorado
Novo Nordisk Investigational Site
Colorado Springs, Colorado
Novo Nordisk Investigational Site
Golden, Colorado
Novo Nordisk Investigational Site
New London, Connecticut
Novo Nordisk Investigational Site
Waterbury, Connecticut
Novo Nordisk Investigational Site
Washington D.C., District of Columbia
Novo Nordisk Investigational Site
Boynton Beach, Florida
Novo Nordisk Investigational Site
Bradenton, Florida
Novo Nordisk Investigational Site
Crystal River, Florida
Novo Nordisk Investigational Site
Daytona Beach, Florida
Novo Nordisk Investigational Site
Jacksonville, Florida
Novo Nordisk Investigational Site
Jacksonville, Florida
Novo Nordisk Investigational Site
Ocala, Florida
Novo Nordisk Investigational Site
Ponte Vedra, Florida
Novo Nordisk Investigational Site
South Miami, Florida
Novo Nordisk Investigational Site
Athens, Georgia
Novo Nordisk Investigational Site
Dunwoody, Georgia
Novo Nordisk Investigational Site
Sandy Springs, Georgia
Novo Nordisk Investigational Site
Suwanee, Georgia
Novo Nordisk Investigational Site
Aurora, Illinois
Novo Nordisk Investigational Site
Topeka, Kansas
Novo Nordisk Investigational Site
Baton Rouge, Louisiana
Novo Nordisk Investigational Site
Baltimore, Maryland
Novo Nordisk Investigational Site
Elkridge, Maryland
Novo Nordisk Investigational Site
North Dartmouth, Massachusetts
Novo Nordisk Investigational Site
City of Saint Peters, Missouri
Novo Nordisk Investigational Site
Kansas City, Missouri
Novo Nordisk Investigational Site
St Louis, Missouri
Novo Nordisk Investigational Site
St Louis, Missouri
Novo Nordisk Investigational Site
New York, New York
Novo Nordisk Investigational Site
Rochester, New York
Showing 40 of 226 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.